Aakash Desai: A must-read for those interested in the cutting-edge advancements in Oncology and Cancer Research
Aakash Desai, shared a post by Alessandro Russo, Medical Oncologist at the University of Messina, on LinkedIn, adding:
“Great working with the amazing team of Sruthi Ranganathan, Aswanth Reddy, Alessandro Russo, Umberto Malapelle.
‘Double Agents in ImmunoOncology: Unmasking the Role of Antibody-Drug Conjugates (ADCs) in Checkpoint Targeting.’
Our article dives deep into how ADCs are revolutionizing checkpoint targeting, specifically focusing on:
- B7-H3
- B7-H4
- PD-L1
- Integrins
A must-read for those interested in the cutting-edge advancements in Oncology and Cancer Research.”
Quoting Alessandro Russo’s post:
“Out now on Critical Reviews in Oncology/Hematology our review on the emerging role of antibody drug conjugates (ADCs) in immune checkpoint targeting. A great effort led by the Aakash Desai! Always a pleasure to work with you!”
Autors: Sruthi Ranganathan, Aswanth Reddy, Alessandro Russo, Umberto Malepelle, Aakash Desai
Source: Aakash Desai/LinkedIn and Alessandro Russo/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023